Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Honest Company Inc (HNST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Honest Company Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $302.38 (market cap $39.89B), while Honest Company Inc trades at $4.01 (market cap $441.42M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 90.4× Honest Company Inc's market cap, and Honest Company Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | HNST | |
|---|---|---|
Market Cap | $39.89B | $441.42M |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $4.95 |
52-Week Low | $278.09 | $2.10 |
Enterprise Value | $38.15B | $362.81M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
HNST trades at $4.01, up 1.26% today, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $0.01, meeting expectations, but maintains negative net income margins. Cash flow from operations improved to $15.12M in 2025, though revenue declined slightly to $371.32M. Analyst sentiment is mixed with 30% buy ratings.
The outlook remains cautious due to persistent unprofitability and competitive pressures, though cost controls and gross margin expansion offer some upside. Key risks include execution challenges in shifting to retail channels and reliance on wipes & personal care for growth. Investors should weigh improving cash flows against weak bottom-line trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →
